Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ezetimibe cost-effective option in statin intolerance

    • 16 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P, Chilcott J.Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. American Journal of Cardiovascular Drugs 8: 419-427, No. 6, 2008

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Ezetimibe cost-effective option in statin intolerance. Pharmacoecon. Outcomes News 571, 3 (2009). https://doi.org/10.2165/00151234-200905710-00004

    Download citation

    Keywords

    • Ezetimibe
    • Cost Ratio
    • Nonfatal Myocardial Infarction
    • Nonfatal Stroke
    • Discount Cost